Literature DB >> 21547898

Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts.

Simona Serratì1, Francesca Margheri, Anastasia Chillà, Elena Neumann, Ulf Müller-Ladner, Maurizio Benucci, Gabriella Fibbi, Mario Del Rosso.   

Abstract

OBJECTIVE: Urokinase plasminogen activator (uPA), uPA receptor (uPAR), and PA inhibitor 1 (PAI-1) have pivotal roles in the proliferation and invasion of several cell types, including synovial fibroblasts (SFs). The aim of this study was to investigate the possibility of controlling the invasion of rheumatoid arthritis (RA) SFs in vitro and in vivo by inhibiting uPA and uPAR.
METHODS: Normal SFs, SFs from patients with RA, and SFs from patients with psoriatic arthritis (PsA) were used. The levels of uPA, uPAR, and PAI-1 were measured by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction analysis of messenger RNA. The activity of uPA was studied by zymography. Proliferation was measured by cell counting, and cell invasion was measured with a Boyden chamber assembled with Matrigel-coated porous filters. Human cartilage and RA SF implantation in the SCID mouse model of RA were used to study cartilage invasion in vivo.
RESULTS: RA SFs and PsA SFs overexpressed uPAR and as a result were more active than their normal counterparts in terms of both Matrigel invasion and proliferation. This effect was counteracted by a specific inhibitor of uPA enzymatic activity (WX-340) and by uPAR antisense treatment. The use of both WX-340 and uPAR antisense treatment in vitro showed cooperative effects in RA SFs that were more intense than the effects of either treatment alone. Significant inhibition of cartilage invasion was obtained in vivo with uPAR antisense treatment, while uPA inhibition was inefficient, either alone or in combination with antisense treatment.
CONCLUSION: The decrease in uPAR expression in RA SFs reduced invasion of human cartilage in vitro and in the SCID mouse model.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547898     DOI: 10.1002/art.30439

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis.

Authors:  Yan Liu; Yun Feng Pan; You-Qiu Xue; Lin-Kai Fang; Xing-Hua Guo; Xin Guo; Meng Liu; Bi-Yao Mo; Meng-Ru Yang; Fang Liu; Yun-Ting Wu; Nancy Olsen; Song Guo Zheng
Journal:  Cell Mol Immunol       Date:  2017-01-16       Impact factor: 11.530

2.  A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Haydyn D T Mertens; Magnus Kjaergaard; Simon Mysling; Henrik Gårdsvoll; Thomas J D Jørgensen; Dmitri I Svergun; Michael Ploug
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

3.  Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.

Authors:  Selene Pérez-García; Mar Carrión; Rebeca Jimeno; Ana M Ortiz; Isidoro González-Álvaro; Julián Fernández; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2013-12-07       Impact factor: 3.444

Review 4.  Altered metabolic pathways regulate synovial inflammation in rheumatoid arthritis.

Authors:  U Fearon; M M Hanlon; S M Wade; J M Fletcher
Journal:  Clin Exp Immunol       Date:  2018-11-11       Impact factor: 4.330

5.  The Effect of SHH-Gli Signaling Pathway on the Synovial Fibroblast Proliferation in Rheumatoid Arthritis.

Authors:  Suping Qin; Dexu Sun; Hui Li; Xiangyang Li; Wei Pan; Chao Yan; Renxian Tang; Xiaomei Liu
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

Review 6.  The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.

Authors:  Benjamin J Buckley; Umar Ali; Michael J Kelso; Marie Ranson
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

7.  Long Non-Coding RNA GAPLINC Promotes Tumor-Like Biologic Behaviors of Fibroblast-Like Synoviocytes as MicroRNA Sponging in Rheumatoid Arthritis Patients.

Authors:  Bi Yao Mo; Xing Hua Guo; Meng Ru Yang; Fang Liu; Xuan Bi; Yan Liu; Lin Kai Fang; Xi Qing Luo; Julie Wang; Joseph A Bellanti; Yun Feng Pan; Song Guo Zheng
Journal:  Front Immunol       Date:  2018-04-10       Impact factor: 7.561

Review 8.  Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.

Authors:  Breanne H Y Gibson; Matthew T Duvernay; Stephanie N Moore-Lotridge; Matthew J Flick; Jonathan G Schoenecker
Journal:  Res Pract Thromb Haemost       Date:  2020-06-14

Review 9.  Dual Role of Chondrocytes in Rheumatoid Arthritis: The Chicken and the Egg.

Authors:  Chia-Chun Tseng; Yi-Jen Chen; Wei-An Chang; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Jeng-Hsien Yen; Po-Lin Kuo
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

Review 10.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.